This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Nominations Pursuant To Advance Notice Policy

Stocks in this article: CUR

DiagnoCure's Board Maintains its Recommendation to Vote for Current Directors

QUEBEC CITY, April 15, 2013 /PRNewswire/ - Following the adoption by its Board of directors of an advance notice policy, DiagnoCure Inc. (TSX: CUR)(OTCQX: DGCRF) (the "Corporation") announces that a shareholder has submitted nominations for election as directors of the Corporation at the upcoming Annual and Special meeting of shareholders of April 29, 2013 at which five directors will be elected.

Nominations Pursuant to the Advance Notice Policy

The Corporation informs its shareholders that three nominations have been received from a shareholder, Mr.  Todd Axelrod, who is proposing Me Pierre Dozois, Mr. Paul Guay and Mr. Hans Mäder as directors. Collectively, these three nominees hold less than 1% of the shares of the Corporation. The Board of Directors of DiagnoCure recommends not to vote for them.

Importance of Continuity for the Future of DiagnoCure

DiagnoCure believes it is important that the skill sets of its board members complement each other; thus, providing for a Board that functions cohesively. The independent Board members of the Corporation have carefully considered the needs of DiagnoCure in selecting the best candidates to act as directors. Because of their wide-ranging experience and expertise with public companies, R&D activities, oncology, urology, administration, private and public partnerships, corporate governance, finance and financing activities, and in the biotechnology and pharmaceutical industries, the team proposed by DiagnoCure provides an optimal balance. Moreover, the arrival of Dr. Jacques Simoneau and Mr. Andy Sheldon to DiagnoCure's Board, has contributed dramatically to the development of a new momentum at the Corporation, which includes a strong focus on increasing shareholder value.

Royalties received from sales of the FDA-approved PROGENSA ® PCA3 assay in the United States increased by 84% in the first quarter of 2013 compared with the same period in 2012. Moreover, a productive dialogue is ongoing with Hologic's management regarding ways to optimize the value of the PROGENSA ® PCA3 assay for both companies. In addition, evidence continues to build in the clinical community supporting the concept that PCA3 can become a product of reference to help better diagnose prostate cancer patients.

DiagnoCure has also intensified its active effort to license the Corporation's Previstageā„¢ GCC technology. The DiagnoCure management team is currently in discussions with potential partners with the right commercial presence in the diagnostic market. Based upon the datasets generated in several clinical studies, DiagnoCure believes that Previstageā„¢ GCC represents a significant advance in clinical practice, providing physicians with a more sensitive tool for staging patients with colorectal cancer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,246.76 -170.09 -0.98%
S&P 500 2,008.55 -12.70 -0.63%
NASDAQ 4,664.5880 -18.8190 -0.40%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs